Open AccessDistinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease
Author(s) -
Sang Hyoung Park,
Badr Al-Bawardy,
Satimai Aniwan,
Sunanda V. Kane,
Nayantara Coelho–Prabhu,
Konstantinos A. Papadakis,
John B. Kisiel,
David H. Bruining,
William A. Faubion,
Laura E. Raffals,
Darrell S. Pardi,
William J. Tremaine,
Michael C. Stephens,
Jeanne Tung,
Sahil Khanna,
Maria Alice V. Willrich,
Edward V. Loftus
Publication year - 2019
Publication title -
crohn's and colitis 360
Language(s) - English
Resource type - Journals
ISSN - 2631-827X
DOI - 10.1093/crocol/otz047
Subject(s) - medicine , adalimumab , cutoff , gastroenterology , inflammatory bowel disease , cohort , disease , infliximab , physics , quantum mechanics
Background and Aims We aimed to evaluate the relationship of serum adalimumab trough levels (ATL) with disease activity of inflammatory bowel disease (IBD) patients in a large, well-characterized referral center-based cohort. Methods We compared serum ATL between those with clinical, biochemical, or endoscopic/radiologic disease activity and those without. Results A total of 236 patients with IBD were included. Higher cutoff levels were associated with endoscopic and/or radiologic responses (cutoff value: 5.3 mcg/mL, P = 0.003) compared with improvement in C-reactive protein (cutoff value: 4.3 mcg/mL, P = 0.031). Conclusions Higher cutoff ATL was associated with endoscopic and/or radiologic response.